Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Finished Goods: 2022-2024

Historic Finished Goods for Gyre Therapeutics (GYRE) over the last 3 years, with Dec 2024 value amounting to $2.6 million.

  • Gyre Therapeutics' Finished Goods rose 84.19% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 84.19%. This contributed to the annual value of $2.6 million for FY2024, which is 91.50% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Finished Goods of $2.6 million as of FY2024, which was up 91.50% from $1.4 million recorded in FY2023.
  • Gyre Therapeutics' Finished Goods' 5-year high stood at $2.6 million during FY2024, with a 5-year trough of $1.4 million in FY2023.
  • Moreover, its 3-year median value for Finished Goods was $1.4 million (2022), whereas its average is $1.8 million.
  • Its Finished Goods has fluctuated over the past 5 years, first declined by 2.43% in 2023, then skyrocketed by 91.50% in 2024.
  • Gyre Therapeutics' Finished Goods (Yearly) stood at $1.4 million in 2022, then fell by 2.43% to $1.4 million in 2023, then spiked by 91.50% to $2.6 million in 2024.